Show simple item record

dc.contributor.authorYe, W.
dc.contributor.authorOlsson-Brown, A.
dc.contributor.authorWatson, R. A.
dc.contributor.authorCheung, V. T. F.
dc.contributor.authorMorgan, Robert David
dc.contributor.authorNassiri, I.
dc.contributor.authorCooper, R.
dc.contributor.authorTaylor, C. A.
dc.contributor.authorAkbani, U.
dc.contributor.authorBrain, O.
dc.contributor.authorMatin, R. N.
dc.contributor.authorCoupe, N.
dc.contributor.authorMiddleton, M. R.
dc.contributor.authorColes, M.
dc.contributor.authorSacco, J. J.
dc.contributor.authorPayne, M. J.
dc.contributor.authorFairfax, B. P.
dc.date.accessioned2021-04-20T08:08:26Z
dc.date.available2021-04-20T08:08:26Z
dc.date.issued2021en
dc.identifier.citationYe W, Olsson-Brown A, Watson RA, Cheung VTF, Morgan RD, Nassiri I, et al. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. Br J Cancer. 2021.en
dc.identifier.pmid33723392en
dc.identifier.doi10.1038/s41416-021-01310-3en
dc.identifier.urihttp://hdl.handle.net/10541/623969
dc.description.abstractBackground: Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear. Methods: Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab-sICB) or combination (nivolumab and ipilimumab-cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed. Results: 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9-33.4) versus not-reached (P = 2.8 × 10-6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment. Conclusions: Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-021-01310-3en
dc.titleCheckpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profilesen
dc.typeArticleen
dc.contributor.departmentOxford University Clinical Academic Graduate School, University of Oxford, Oxforden
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]
refterms.dateFOA2021-04-26T08:18:58Z


Files in this item

Thumbnail
Name:
33723392.pdf
Size:
971.3Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record